MLICM
TRDA icon

Metropolitan Life Insurance Company (MetLife)’s Entrada Therapeutics TRDA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,212
Closed -$17.2K – 1942
2024
Q1 		$17.2K Hold
1,212
– – ﹤0.01% 1935
2023
Q4 		$18.3K Hold
1,212
– – ﹤0.01% 1954
2023
Q3 		$19.1K Hold
1,212
– – ﹤0.01% 1919
2023
Q2 		$18.4K Buy
+1,212
New +$16.7K ﹤0.01% 1978

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TRDA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Entrada Therapeutics (TRDA) in Q2 2024, closing a stake of 1,212 shares — an estimated $17.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TRDA in Q2 2023 and held it in 4 quarters. The position peaked at $19.1K in Q3 2023. 83 funds tracked by Wall St. Rank hold TRDA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Entrada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,212 Entrada Therapeutics shares in Q2 2024, an estimated $17.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Entrada Therapeutics in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Entrada Therapeutics position peaked at $19.1K in Q3 2023.
  • 83 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.